Gabriel Cairo Nunes

Gabriel Cairo Nunes

Auto-generated profile, based on publicly available information

Gabriel Cairo Nunes

Unidade de Cirurgia Bariatrica e Metabolica, Departamento de Gastroenterologia, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
EFEduardo Luzía França
Eduardo Luzía França
AHAdenilda Cristina Honório-França
Adenilda Cristina Honório-França
GNGabriel Triches Nunes
Gabriel Triches Nunes
DFDanny Laura Gomes Fagundes
Danny Laura Gomes Fagundes
PMPatrícia Gelli Feres Marchi
Patrícia Gelli Feres Marchi
LMLucélia Campelo Albuquerque Moraes
Lucélia Campelo Albuquerque Moraes
Purpose: Clinical and epidemiological studies have indicated that breastfeeding has a protective effect on breast cancer risk. Protein-based drugs, including antibodies, are being developed to attain better forms of cancer therapy. Secretory IgA (SIgA) is the antibody class in human breast milk, and its activity can be linked to the protective effect of breastfeeding. The aim of this study was to investigate the effect of polyethylene glycol (PEG) microspheres with adsorbed SIgA on MCF-7 human breast cancer cells.
Methods:
The PEG microspheres were characterized by flow cytometry and fluorescence microscopy. The MCF-7 cells were obtained from American Type Culture Collection. MCF-7 cells were pre-incubated for 24 hours with or without SIgA (100 ng/mL), PEG microspheres or SIgA adsorbed in PEG microspheres (100 ng/mL). Viability, intracellular calcium release, and apoptosis in MCF-7 cells were determined by flow cytometry. Results: Fluorescence microscopy and flow cytometry analyses revealed that SIgA was able to adsorb to the PEG microspheres. The MCF-7 cells that were incubated with PEG microspheres with adsorbed SIgA showed decreased viability. MCF-7 cells that were incubated with SIgA or PEG microspheres with adsorbed SIgA had increased intracellular Ca2+ levels. In the presence of SIgA, an increase in the percentage of apoptotic cells was observed. The highest apoptosis index was observed when the cells were treated with PEG microspheres with adsorbed SIgA. Conclusion: These data suggest that colostral SIgA adsorbed to PEG microspheres has antitumor effects on human MCF-7 breast cancer cells and that the presence of large amounts of this protein in secreted breast milk may provide protection against breast tumors in women who breastfed.

1 August 2017 in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Verified
Journal Article
Closed access
GNGabriel C. Nunes
Gabriel C. Nunes
DPDenis Pajecki
Denis Pajecki
MMMARIA EDNA DE MELO
MARIA EDNA DE MELO
MMMarcio Corrêa Mancini
Marcio Corrêa Mancini
RCRoberto de Cleva
Roberto de Cleva
MSMarco A. Santo
Marco A. Santo
The intragastric balloon (IGB) is an endoscopic device for the treatment of obesity. Best results are observed in patients who follow a dietary program but few studies have assessed the results of this treatment in patients with different degrees of obesity. The aim of this study is to compare the efficacy of IGB in patients with different degrees of obesity. A total of 2002 patients with IGB were retrospectively evaluated and were divided into groups according to initial body mass index (BMI) range, as follows: group 1, 27 to 29.9 kg/m; group 2, 30 to 34.9 kg/m; group 3, 35 to 39.9 kg/m; group 4, 40 to 44.9 kg/m; group 5, ≥45 kg/m. Weight was assessed in 3 different times: before (T0), 1 month (T1), 6 months (T2), and 6 months after removal of the IGB (T3). A total of 946 patients lost follow-up. Overall, 40 (3.78%) removed the device before programmed by intolerance, and 1016 patients completed the 6-month treatment. The mean weight loss was 18.9%, excess weight loss 60.1% and an BMI reduction of 6.76 points. 6 months after removal of the balloon 842 patients had continued follow-up (82.8%). At this time, weight loss was 19.84%, excess weight loss was 59.49%, and BMI reduction of 7.06 points. In all groups there was statistical difference between the times T0 and T1 and between T1 and T2 (P<0.001). There was no statistical difference between T2 and T3, in any group. IGB provided sustained weight loss in patients who remained in dietary follow-up for 1 year.

1 January 2019 in Clinics
Verified
Journal Article
Open access
DPDenis Pajecki
Denis Pajecki
LOLea Campos de Oliveira
Lea Campos de Oliveira
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
MSMarcela de Souza-Basqueira
Marcela de Souza-Basqueira
ADAnna Carolina Batista Dantas
Anna Carolina Batista Dantas
MSMarco Aurélio Santo
Marco Aurélio Santo
The gut microbiota is associated with obesity and weight loss after bariatric surgery and has been related to its changing pattern. Exactly how the bacterial population affects weight loss and the results of surgery remain controversial. This study aimed to evaluate the intestinal microbiota of superobese patients before and after gastric bypass surgery (RYGB). DNA fragments for the microbiota obtained from stool samples collected from nine superobese patients before and after bariatric surgery were sequenced using Ion Torrent. We observed that with a mean follow-up of 15 months, patients achieved 55.9% excess weight loss (EWL). A significant population reduction in the Proteobacteria phylum (11 to 2%, p=0.0025) was observed after surgery, while no difference was seen in Firmicutes and Bacteroidetes. Further analyses performed with two specific individuals with divergent clinical outcomes showed a change in the pattern between them, with a significant increase in Firmicutes and a decrease in Bacteroidetes in the patient with less weight loss (%EWL 50.79 vs. 61.85). RYGB affects the microbiota of superobese patients, with a significant reduction in Proteobacteria in patients with different weight loss, showing that different bacteria may contribute to the process.

9 June 2023 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
AHAnna Hoff
Anna Hoff
MNManoel Galvao Neto
Manoel Galvao Neto
GNGabriel Nunes
Gabriel Nunes
EGEduardo Grecco
Eduardo Grecco
ATAmny Acosta Then
Amny Acosta Then
RSReem Z. Sharaiha
Reem Z. Sharaiha